Previous 10 | Next 10 |
Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m...
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval for Alexion Pharmaceuticals' ( ALXN -1.5% ) Ultomiris (ravulizumab) for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) with hemolysis with clinical sym...
- Final European Commission decision anticipated in June 2019 - - ULTOMIRIS has the potential to become the new standard of care for both complement inhibitor-naïve patients and patients switching from SOLIRIS ® (eculizumab) - Alexion Pharmaceuticals, Inc. (NASDA...
Alexion Pharmaceuticals, Inc. (ALXN) Q1 2019 Results Earnings Conference Call April 25, 2019, 08:00 AM ET Company Participants Susan Altschuller - VP, IR Ludwig Hantson - CEO & Director Paul Clancy - EVP & CFO John Orloff - EVP and Head, Research & Development Bri...
The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2019 Q1 earnings Read more ...
Alexion Pharmaceuticals ( ALXN ) Q1 results : Revenues: $1,140.4M (+22.5%); Soliris: $962M (+20.2%); Ultomiris: $24.6M; Strensiq: $130.1M (+17.5%); Kanuma: $23.5M (+19.9%). More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more ......
1Q19 total revenues of $1,140.4 million, a 23 percent increase over 1Q18 and a 26 percent volume increase 1Q19 GAAP diluted EPS of $2.61; non-GAAP diluted EPS of $2.39 Strong U.S. launch underway for ULTOMIRIS ® (ravulizumab-cwvz) in adults with paroxysmal noctural hemoglobin...
Mustang Bio, Inc. ( MBIO ) soared last Thursday after the very successful results of its gene therapy, MB-107, for X-linked Severe Combined Immunodeficiency, or X-SCID, were published in the New England Journal of Medicine. The therapy, licensed from the St. Jude Children's Research Hospital, ...
News, Short Squeeze, Breakout and More Instantly...
Alexion Pharmaceuticals Inc. Company Name:
ALXN Stock Symbol:
NASDAQ Market:
Alexion Pharmaceuticals Inc. Website:
AstraZeneca (NASDAQ: AZN) hopes to soon close its planned acquisition of Alexion Pharmaceuticals (NASDAQ: ALXN) . The only hurdle left to jump is obtaining approval from United Kingdom regulators. In this Motley Fool Live video recorded on July 7 , Motley Fool contri...
This week, pharma and biotech giant AstraZeneca (NASDAQ: AZN) cleared its final hurdle in the proposed acquisition of orphan drug pharma company Alexion Pharmaceuticals (NASDAQ: ALXN) when it announced that the deal had received clearance from the United Kingdom's Compet...